Burning Rock Biotech Statistics
Want to see BNR full AI Analyst Report?
Burning Rock Biotech (BNR) Stock Statistics & Valuation Metrics
Total Valuation
Burning Rock Biotech has a market cap or net worth of $139.79M. The enterprise value is $35.78M.
- Market Cap
- $139.79M
- Enterprise Value
- $35.78M
Share Statistics
Burning Rock Biotech has 8,813,858 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 8,813,858
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Burning Rock Biotech’s return on equity (ROE) is -0.10 and return on invested capital (ROIC) is -9.28%.
- Return on Equity (ROE)
- -0.10
- Return on Assets (ROA)
- -0.07
- Return on Invested Capital (ROIC)
- -9.28%
- Return on Capital Employed (ROCE)
- -0.10
- Revenue Per Employee
- 808.95K
- Profits Per Employee
- -82.98K
- Employee Count
- 667
- Asset Turnover
- 0.66
- Inventory Turnover
- 2.40
Valuation Ratios
The current PE Ratio of Burning Rock Biotech is -1.38. Burning Rock Biotech’s PEG ratio is -0.04.
- PE Ratio
- -1.38
- PS Ratio
- 0.19
- PB Ratio
- 0.19
- Price to FCF
- -5.34
- Price to Operating Cash Flow
- -7.87
- PEG Ratio
- -0.04
Income Statement
In the last 12 months, Burning Rock Biotech had revenue of 539.57M and earned -55.35M in profits. Earnings per share was -49.60.
- Revenue
- 539.57M
- Gross Profit
- 402.91M
- Operating Income
- -54.84M
- Pretax Income
- -53.79M
- Net Income
- -55.35M
- EBITDA
- -32.00M
- Earnings Per Share (EPS)
- -49.60
Cash Flow
In the last 12 months, operating cash flow was -12.22M and capital expenditures -5.25M, giving a free cash flow of -17.47M billion.
- Operating Cash Flow
- -12.22M
- Free Cash Flow
- -17.47M
- Free Cash Flow per Share
- -16.09
Dividends & Yields
Burning Rock Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -18.68%
- Earnings Yield
- -70.68%
Stock Price Statistics
- Beta
- 1.94
- 52-Week Price Change
- 17.40%
- 50-Day Moving Average
- 13.77
- 200-Day Moving Average
- 14.92
- Relative Strength Index (RSI)
- 52.08
- Average Volume (3m)
- 35.07K
Important Dates
Burning Rock Biotech upcoming earnings date is Nov 17, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Sep 02, 2026
- Next Earnings Date
- Nov 17, 2026
- Ex-Dividend Date
- ―
Financial Position
Burning Rock Biotech as a current ratio of 2.99, with Debt / Equity ratio of 8.06%
- Current Ratio
- 2.99
- Quick Ratio
- 2.76
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 13.70
- Interest Coverage Ratio
- -1828.17
Taxes
In the past 12 months, Burning Rock Biotech has paid 1.56M in taxes.
- Income Tax
- 1.56M
- Effective Tax Rate
- -0.03
Enterprise Valuation
Burning Rock Biotech EV to EBITDA ratio is 6.64, with an EV/FCF ratio of 16.06.
- EV to Sales
- -0.56
- EV to EBITDA
- 6.64
- EV to Free Cash Flow
- 16.06
- EV to Operating Cash Flow
- 22.96
Balance Sheet
Burning Rock Biotech has $419.26M in cash and marketable securities with $45.13M in debt, giving a net cash position of $374.13M billion.
- Cash & Marketable Securities
- $419.26M
- Total Debt
- $45.13M
- Net Cash
- $374.13M
- Net Cash Per Share
- $42.45
- Tangible Book Value Per Share
- $457.65
Margins
Gross margin is 74.55%, with operating margin of -12.99%, and net profit margin of -13.59%.
- Gross Margin
- 74.55%
- Operating Margin
- -12.99%
- Pretax Margin
- -13.27%
- Net Profit Margin
- -13.59%
- EBITDA Margin
- -8.43%
- EBIT Margin
- -13.23%
Analyst Forecast
The average price target for Burning Rock Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -3.65%
- EPS Growth Forecast
- 51.30%
Scores
- Smart Score
- 3
- AI Score
- 47

